Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
Pfizer Medical / TUKYSA prescribing information
Product / population
TUKYSA tablets for the product-specific HER2-positive breast and colorectal cancer combinations. Companion-drug and indication restrictions remain separate.
Renal method
Cockcroft-Gault CrCl, mL/min; alternative filtration markers when appropriate
Source revision
1/2023
Retrieved
2026-09-09
Local review status
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
Creatinine transport effects do not rule out acute kidney injury
An isolated creatinine rise can reflect transport effects, but diarrhea-related volume depletion can also cause true injury. The combination-specific severe-renal restriction remains.
What to reconcile: Assess the clinical course and alternative filtration markers where appropriate; reconcile companion-drug labels.
Pfizer Medical / product prescribing information · TUKYSA tablets for the product-specific HER2-positive breast and colorectal cancer combinations. Companion-drug and indication restrictions remain separate.
Renal method: Cockcroft-Gault CrCl, mL/min; alternative filtration markers when appropriate Source date: 1/2023 Retrieved: 2026-09-09
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
No tucatinib adjustment is recommended at CrCl 30-89 mL/min. The trastuzumab/capecitabine combination is not recommended at Cockcroft-Gault CrCl <30 mL/min in this source. Severe-impairment pharmacokinetics are unknown; this does not supply an alternative severe-renal regimen.
Tucatinib can raise serum creatinine through tubular transport effects without lowering filtration. Consider alternative renal-function markers for a persistent isolated rise. This is not permission to dismiss kidney injury: severe diarrhea can cause dehydration, hypotension and acute kidney injury. Assess the clinical course and the exact companion-drug labels.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.